drugset / Trial / NCT02215356

Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer

NCT02215356

Phase 2 Unknown 120 enrolled Betta Pharmaceuticals Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomised, multi-center, controlled trial is designed to assess the efficacy and safety of icotinib with concurrent radiotherapy versus chemotherapy with concurrent radiotherapy in non-small cell lung cancer

Timeline

Start
2014-08
Primary completion
2018-08
Completion
2019-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cisplatin Other / unclassified 50 mg/m2 Intravenous
Comparator Etoposide Small molecule 50 mg/m2 Intravenous
Subject Icotinib Small molecule 125 mg Oral